Table 1

Baseline characteristics of patients with SLE

VariablenN
Female, n (%)355 (89.6)396
Age35 (27, 48)396
Disease duration (months)12 (2, 72)396
Fever, n (%)95 (24.0)396
Rash, n (%)173 (43.7)396
Alopecia, n (%)132 (33.3)396
Mucosal ulcers, n (%)50 (12.6)396
Arthritis, n (%)76 (19.2)396
Myositis, n (%)11 (2.8)396
Vasculitis, n (%)75 (18.9)396
Pleuritis, n (%)58 (14.6)396
Pericarditis, n (%)48 (12.1)396
Proteinuria, n (%)154 (38.9)396
Urinary casts, n (%)56 (14.1)396
Haematuria, n (%)173 (43.7)396
Pyuria, n (%)125 (31.6)396
Cardiac involvement, n (%)29 (7.3)396
Pulmonary involvement, n (%)21 (5.3)396
Neuropsychiatric involvement, n (%)27 (6.8)396
ANA, n (%)383 (97.7)392
Anti-dsDNA, n (%)237 (59.8)396
Anti-Smith, n (%)138 (35.0)394
Anti-U1RNP, n (%)166 (42.2)393
Anti-ribosomal P protein, n (%)93 (23.7)393
Anti-Ro60, n (%)240 (61.1)393
Anti-Ro52, n (%)205 (52.2)393
Anti-SSB, n (%)63 (16.0)393
Anti-centromere protein B, n (%)10 (2.5)393
Anti-Scl70, n (%)5 (1.3)393
Anti-Jo1, n (%)0 (0)393
Antiphospholipid antibodies, n (%)44 (19.1)230
Direct Coombs’ test, n (%)30 (25.0)120
Leucocyte count (109 /L)4.2 (3.1, 6.4)396
Leucopenia, n (%)87 (22.0)396
Neutrophil count (109 /L)2.8 (1.9, 4.7)396
Neutropenia, n (%)37 (9.3)396
Lymphocyte count (109 /L)1.0 (0.6, 1.4)396
lymphopenia, n (%)145 (36.6)396
Haemoglobin (g/L)110 (94, 124)396
Anaemia, n (%)199 (50.3)396
Platelet count (109 /L)167.5 (96.3, 218.8)396
Thrombocytopenia, n (%)105 (26.5)396
Severe thrombocytopenia, n (%)41 (10.3)396
Erythrocyte sedimentation rate (mm/H)32 (14, 52)382
C reactive protein (mg/L)5.9 (5.2, 9.2)396
Complement 3 (g/L)0.550 (0.380, 0.778)396
Low complement 3, n (%)304 (76.8)396
Complement 4 (g/L)0.099 (0.064, 0.150)396
Low complement 4, n (%)305 (77.0)396
SLEDAI 2000 value13 (8, 19)396
SLEDAI 2000 disease activity grading, n (%)396
 SLEDAI 2000 score<772 (18.2)
 SLEDAI 2000 score≥7324 (81.8)
SLE-DAS value15.32 (7.90, 24.45)396
SLE-DAS disease activity grading, n (%)396
 SLE-DAS score≤7.6496 (24.2)
 SLE-DAS score>7.64300 (75.8)
Glucocorticoid dose grading, n (%)396
 Free6 (1.5)
 Low66 (16.7)
 Moderate108 (27.3)
 High189 (47.7)
 Intravenous pulse27 (6.8)
Gammaglobulin, n (%)40 (10.1)396
Hydroxychloroquine, n (%)216 (54.5)396
Immunosuppressants, n (%)193 (48.7)396
Biologics, n (%)18 (4.5)396
  • Except where indicated otherwise, values are median (P25, P75).

  • ANA, anti-nuclear antibody; Anti-SSB, anti-Sjögren’s syndrome B; SLEDAI 2000, systemic lupus erythematosus disease activity index 2000; SLE-DAS, systemic lupus erythematosus disease activity score.